Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 201–300 of 1,000
Martin-Padura, I., Gregato, G., Marighetti, P., Mancuso, P., Calleri, A., Corsini, C., Pruneri, G., Manzotti, M., Lohsiriwat, V., Rietjens, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1739 · Cited by 149
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
“In a preclinical trial on lung cancer, the depletion of CAF significantly reduced the number of metastases (31, 32).”
BackgroundMethodGross, G., & Eshhar, Z. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124844 · Cited by 161
ZI, F., HE, J., HE, D., LI, Y., YANG, L., & CAI, Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3197 · Cited by 141
Chen, Q., Li, J., Han, F., Meng, Q., Wang, H., Wei, Q., Li, Z., Li, F., Xie, E., Qin, X., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202201067 · Cited by 170
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
Hasmim, M., Messai, Y., Ziani, L., Thiery, J., Bouhris, J.-H., Noman, M. Z., & Chouaïb, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00482 · Cited by 160
“As such, CAFs can potentially affect both innate and adaptive antitumor immune response by increasing the recruitment to tumor of myeloid-derived suppressive cells (MDSC), by decreasing antigen presentation, by increasing the numbers of Tregs, by decreasing T-cell proliferation, cytotoxic T-cell (CTL) function and mat…”
BackgroundFerdinandus, J., Costa, P. F., Kessler, L., Weber, M., Hirmas, N., Kostbade, K., Bauer, S., Schüler, M., Ahrens, M., Schildhaus, H., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262468 · Cited by 200
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
Cruz-Bermúdez, A., Laza-Briviesca, R., Vicente-Blanco, R. J., García-Grande, A., Coronado, M. J., Laine-Menéndez, S., Alfaro, C., Sanchez, J. C., Franco, F., Calvo, V., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.450 · Cited by 137
Gu, X., Zhu, Y., Su, J., Wang, S., Su, X., Ding, X., Jiang, L., Fei, X., & Zhang, W. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103209 · Cited by 148
“As mounting evidence underscores the role of CAFs in regulating tumor immunity and progression, they have become a significant target for cancer treatment [14 – 17].”
Jena, B. C., Sarkar, S., Rout, L., & Mandal, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.002 · Cited by 150
Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 155
Fibroblast Activation Protein-α
Kelly, T. J., Huang, Y., Simms, A. E., & Mazur, A. (2012) · International review of cytology · doi:10.1016/b978-0-12-394308-8.00003-0 · Cited by 158
Yamaguchi, H., & Sakai, R. (2015) · Cancers · doi:10.3390/cancers7040876 · Cited by 148
“These results contradict other studies [54,59,60] and this discrepancy could be caused by the use of different animal models (e.”
BackgroundResultToll-Like Receptor 9 Agonists in Cancer
Karapetyan, L., Luke, J. J., & Davar, D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s247050 · Cited by 147
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 144
“CAF markers that can be targeted include FAP and fibronectin and are currently being investigated in tumor therapies, as possible monotherapy or in combination with chemotherapy or immune modulators (Kraman et al., 2010; Lindner et al., 2018; Özdemir et al., 2015).”
BackgroundWong, H. Y., Sheng, Q., Hesterberg, A. B., Croessmann, S., Rios, B. L., Giri, K. R., Jackson, J., Miranda, A. X., Watkins, E., Schaffer, K. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33780-1 · Cited by 142
Wehrli, M., Guinn, S. R., Birocchi, F., Kuo, A., Sun, Y., Larson, R. C., Almazan, A. J., Scarfò, I., Bouffard, A. A., Bailey, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3841 · Cited by 140
Zou, J., Jiang, C., Hu, Q., Jia, X., Wang, S., Wan, S., Mao, Y., Zhang, D., Zhang, P., Dai, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55658-0 · Cited by 142
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review
Chang, J. H., Jiang, Y., & Pillarisetty, V. G. (2016) · Medicine · doi:10.1097/md.0000000000005541 · Cited by 151
Sandberg, T. P., Stuart, M. P. M. E., Oosting, J., Tollenaar, R. A. E. M., Sier, C. F. M., & Mesker, W. E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5462-2 · Cited by 135
Lunardi, S., Jamieson, N. B., Lim, S. Y., Griffiths, K., Carvalho‐Gaspar, M., Al‐Assar, O., Yameen, S., Carter, R. C., McKay, C. J., Spoletini, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2519 · Cited by 149
“However, the mechanisms by which PSCs influence the immunoresponse are not completely understood and remain subject of active research [10, 11].”
Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets
Whittle, M. C., & Hingorani, S. R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.044 · Cited by 137
Darragh, L. B., Oweida, A. J., & Karam, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03154 · Cited by 137
Hu, S., Lu, H., Xie, W., Wang, D., Shan, Z., Xing, X., Wang, X.-M., Fang, J., Dong, W., Dai, W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157649 · Cited by 154
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 130
FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
Hicks, R. J., Roselt, P. D., Kallur, K. G., Tothill, R. W., & Mileshkin, L. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.256271 · Cited by 139
The fibroblast as a therapeutic target in rheumatoid arthritis
Filer, A. D. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.02.006 · Cited by 141
Ziani, L., Safta-Saadoun, T. B., Gourbeix, J., Cavalcanti, A., Robert, C., Favre, G., Chouaib, S., & Thiery, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15540 · Cited by 128
“During the past few years, it has also been either directly demonstrated or suggested that these activated tumor-associated fibroblasts can affect both the innate and the adaptive antitumor immune response, especially by the secretion of pro-inflammatory and immunosuppressive factors in the tumor microenvironment [19,…”
BackgroundMori, Y., Novruzov, E., Schmitt, D. R., Cardinale, J., Watabe, T., Choyke, P. L., Alavi, A. A., Haberkorn, U., & Giesel, F. L. (2024) · npj Imaging · doi:10.1038/s44303-024-00053-z · Cited by 140
Jia, D., Liu, Z., Deng, N., Tan, T. Z., Huang, R. Y.-J., Taylor-Harding, B., Cheon, D.-J., Lawrenson, K., Wiedemeyer, W. R., Walts, A. E., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.001 · Cited by 130
The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas
Mezawa, Y., & Orimo, A. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2471-1 · Cited by 134
“(Feig et al. 2013; Kraman et al. 2010).”
BackgroundKeane, F. M., Nadvi, N. A., Yao, T., & Gorrell, M. D. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08051.x · Cited by 124
Pancreatic cancer and its stroma: A conspiracy theory
Xu, Z., Pothula, S. P., Wilson, J. S., & Apte, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11216 · Cited by 141
Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release
Szot, C., Saha, S., Zhang, X. M., Zhu, Z., Hilton, M. B., Morris, K., Seaman, S., Dunleavey, J. M., Hsu, K.-S., Yu, G.-J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120481 · Cited by 127
Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis
Muliaditan, T., Caron, J., Okesola, M., Opzoomer, J. W., Kosti, P., Georgouli, M., Gordon, P., Lall, S., Kuzeva, D. M., Pedro, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05346-7 · Cited by 133
Self-citationA potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice
Fang, J., Xiao, L., Joo, K., Liu, Y., Zhang, C., Liu, S., Conti, P. S., Li, Z., & Wang, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.29831 · Cited by 120
Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells
Poggi, A. D., Musso, A., Dapino, I., & Zocchi, M. R. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.03.001 · Cited by 135
Belle, J. I., Sen, D., Baer, J. M., Liu, X., Lander, V. E., Ye, J., Sells, B. E., Knolhoff, B. L., Ahmad, F. F., Kang, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0428 · Cited by 136
Key role of pancreatic stellate cells in pancreatic cancer
Pothula, S. P., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.035 · Cited by 131
Fabre, M., Ferrer, C., Domínguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., Eisler, S. A., Kontermann, R. E., Pfizenmaier, K., Lee, S. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2238 · Cited by 126
“Recently, studies have shown that FAP-expressing CAFs are a nonredundant, immunosuppressive component of the tumor microenvironment (7).”
BackgroundResultInfluentialXiang, X., Niu, Y., Wang, Z.-H., Ye, L., Peng, W., & Zhou, Q. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.006 · Cited by 138
Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies
Rucki, A. A., & Zheng, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2237 · Cited by 133
Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy
Zhang, T., Jia, Y., Yu, Y., Zhang, B., Xu, F., & Guo, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114319 · Cited by 113
Tchou, J., Zhang, P. J., Bi, Y., Satija, C., Marjumdar, R., Stephen, T. L., Lo, A., Chen, H., Mies, C., June, C. H., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.06.016 · Cited by 112
Stromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 120
Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 133
CD40 immunotherapy for pancreatic cancer
Vonderheide, R. H., Bajor, D. L., Winograd, R., Evans, R. A., Bayne, L. J., & Beatty, G. L. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1427-5 · Cited by 114
Poplawski, S. E., Lai, J. H., Li, Y., Jin, Z., Liu, Y., Wu, W., Wu, Y., Zhou, Y., Sudmeier, J. L., Sanford, D. G., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400351a · Cited by 116
Increased Soluble CD155 in the Serum of Cancer Patients
Iguchi‐Manaka, A., Okumura, G., Kojima, H., Cho, Y., Hirochika, R., Bando, H., Sato, T., Yoshikawa, H., Hara, H., Shibuya, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152982 · Cited by 119
“Mice were monitored for tumor size (the long (L) and short (S) dimensions) by using calipers once a week, and the tumor volumes were calculated by the equation: volume = (L × S(2)) / 2, as previously described [22].”
MethodCancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy
Barrett, R., & Puré, E. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.03.004 · Cited by 117
Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
Heinrich, M. A., Mostafa, A. M. R. H., Morton, J. P., Hawinkels, L. J. A. C., & Prakash, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.018 · Cited by 126
Zhu, Y., Li, X., Wang, L., Hong, X., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.988295 · Cited by 125
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 125
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117
“These results suggest that the lack of synergy observed between TBRI inhibition and PD-1 blockade in this preclinical melanoma model is at least partially related to diminished PD-1/PD-L1 expression in the TME.”
BackgroundInfluentialKawase, T., Yasui, Y., Nishina, S., Hara, Y., Yanatori, I., Tomiyama, Y., Nakashima, Y., Yoshida, K., Kishi, F., Nakamura, M., et al. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0340-0 · Cited by 111
“In addition, some biological properties of FAP such as matrix production supportive for cell motility, immune suppression, and angiogenesis during the extensive desmoplastic response associated with this cancer have been demonstrated [17–20].”
BackgroundRegulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 119
Krisnawan, V. E., Stanley, J. A., Schwarz, J. K., & DeNardo, D. G. (2020) · Cancers · doi:10.3390/cancers12102916 · Cited by 122
Koczorowska, M. M., Tholen, S., Bucher, F., Lutz, L., Kizhakkedathu, J. N., De Wever, O., Wellner, U. F., Biniossek, M. L., Stahl, A., Lassmann, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.001 · Cited by 112
Ruze, R., Song, J., Yin, X., Chen, Y., Xu, R., Wang, C., & Zhao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01376-w · Cited by 125
Wang, E., Wang, L.-C., Tsai, C., Bhoj, V. G., Gershenson, Z., Moon, E. K., Newick, K., Sun, J., Lo, A., Baradet, T. C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0054 · Cited by 121
“These stromal cells support tumor growth and limit immunologic reactions against the tumor (32).”
BackgroundInsidious Changes in Stromal Matrix Fuel Cancer Progression
Miles, F. L., & Sikes, R. A. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0535 · Cited by 111
Positive and negative influence of the matrix architecture on antitumor immune surveillance
Peranzoni, E., Rivas-Caicedo, A., Bougherara, H., Salmon, H., & Donnadieu, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1339-8 · Cited by 117
“Interestingly, selective elimination of FAP-expressing cells, using transgenic mice that express the diphtheria toxin receptor under the control of the FAP promoter, was indeed shown to reduce tumor growth by a process involving an antitumor immune response [125].”
BackgroundCancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment
Kim, I., Choi, S., Yoo, S., Lee, M., & Kim, I. (2022) · Cancers · doi:10.3390/cancers14143321 · Cited by 118
Functional subsets of mesenchymal cell types in the tumor microenvironment
Cortez, E., Roswall, P., & Pietras, K. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.010 · Cited by 116
“depleted CAF from mice by means of a transgenic approach in which the diphtheria toxin receptor was expressed under the FAP promoter [29].”
MethodCan Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Puré, E., & Lo, A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0011 · Cited by 111
“Genetic approaches have been used to conditionally ablate either SMAþ cells in mouse models of pancreatic cancer (27) or FAPþ stromal cells in related models of pancreatic cancer as well as a syngeneic transplant model of lung cancer (100).”
BackgroundMethodInfluentialShahvali, S., Rahiman, N., Jaafari, M. R., & Arabi, L. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01308-9 · Cited by 118
“A resembled depleting FAP-expressing cells in a subcutaneous model of pancreatic ductal adenocarcinoma also led to immunological inhibition of tumor growth in vivo [101].”
BackgroundDeterminants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
“Importantly, FAP+ CAFs are also the main producers of CXCL-12 in PDAC, and their specific depletion increases immunological control over tumor growth (Kraman et al., 2010; Feig et al., 2013).”
BackgroundVaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer
Cappello, P., Rolla, S., Chiarle, R., Principe, M., Cavallo, F., Perconti, G., Feo, S., Giovarelli, M., & Novelli, F. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.020 · Cited by 110
Sun, X., Cui, B., Yuan, B., Wang, X., Fan, L., Yu, D., He, Z., Sheng, L., Liu, J., & Lu, J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003359 · Cited by 110
Modulation of TNF-Induced Macrophage Polarization by Synovial Fibroblasts
Donlin, L. T., Jayatilleke, A., Giannopoulou, E. G., Kalliolias, G. D., & Ivashkiv, L. B. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400486 · Cited by 103
Kashima, H., Noma, K., Ohara, T., Kato, T., Katsura, Y., Komoto, S., Sato, H., Katsube, R., Ninomiya, T., Tazawa, H., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31953 · Cited by 117
Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions
Niebel, D., de Vos, L., Fetter, T., Braegelmann, C., & Wenzel, J. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00774-8 · Cited by 114
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression
Wilson, J. S., Pirola, R. C., & Apte, M. V. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00052 · Cited by 120
“Depletion of the cells expressing FAP-α enabled immune response-associated tumor regression, supporting the notion that FAP-α might act as an immune suppressor in pancreatic cancer (Kraman et al., 2010).”
BackgroundMolecular mechanisms involved in dendritic cell dysfunction in cancer
Tang, M., Diao, J., & Cattral, M. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2317-8 · Cited by 113
Clancy, H. A., Sun, H., Passantino, L., Kluz, T., Muñoz, A. B., Zavadil, J., & Costa, M. (2012) · Metallomics · doi:10.1039/c2mt20074k · Cited by 108
Zhang, Y., & Ertl, H. C. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7818 · Cited by 105
“tumor-specific immune responses [20-23]; however the underlying mechanisms remain poorly understood.”
BackgroundMao, X., Tey, S. K., Yeung, C. L. S., Kwong, E. M. L., Fung, Y. M. E., Chung, C. Y., Mak, L., Wong, D. K.-H., Yuen, M., Ho, J., et al. (2020) · Advanced Science · doi:10.1002/advs.202002157 · Cited by 109
Freeman, P., & Mielgo, A. (2020) · Cancers · doi:10.3390/cancers12092687 · Cited by 102
Zhou, S., Zhen, Z., Paschall, A. V., Xue, L., Yang, X., Bebin Blackwell, A., Cao, Z., Zhang, W., Wang, M., Teng, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202007017 · Cited by 92
Targeting the Microenvironment in Advanced Colorectal Cancer
Tauriello, D. V. F., & Batlle, E. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.001 · Cited by 116
Ogawa, Y., Masugi, Y., Abe, T., Yamazaki, K., Ueno, A., Fujii-Nishimura, Y., Hori, S., Yagi, H., Abe, Y., Kitago, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2298 · Cited by 98
Cancer-Associated Fibroblasts as Targets for Immunotherapy
Kakarla, S., Song, X.-T., & Gottschalk, S. (2012) · Immunotherapy · doi:10.2217/imt.12.112 · Cited by 103
Cheng, L., Wang, Y., Wu, R., Ding, T., Xue, H., Gao, C., Li, X., & Wang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709178 · Cited by 108
The impact of hypoxia in pancreatic cancer invasion and metastasis
Díaz, B., & Yuen, A. (2014) · Hypoxia · doi:10.2147/hp.s52636 · Cited by 116
Vaish, U., Jain, T., Are, A. C., & Dudeja, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413408 · Cited by 110
Zhu, Y.-H., Zheng, J.-H., Jia, Q.-Y., Duan, Z., Yao, H., Yang, J., Sun, Y., Jiang, S.-H., Liu, D., & Huo, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00741-1 · Cited by 111
Fischer, E., Chaitanya, K., Wüest, T., Wadle, A., Scott, A. M., van den Broek, M. F., Schibli, R., Bauer, S., & Renner, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0644 · Cited by 107
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Mediavilla-Varela, M., Luddy, K., Noyes, D., Khalil, F. K., Neuger, A. M., Soliman, H., & Antonia, S. J. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25643 · Cited by 100
“Ablation of these cells in established tumors resulted in rejection mediated by TNF-α and interferon-γ.(16) CAFs also enhance tumor-promoting inflammation(17) and therefore contribute to tumor progression.”
BackgroundLevesque, C., & Nelson, P. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030510 · Cited by 107
“In models of pancreatic and lung cancer, activated fibroblasts were further shown to shape tumor microenvironments through immune control and T-cell exclusion (Kraman et al. 2010; Feig et al. 2013).”
BackgroundNew Strategies for the Treatment of Solid Tumors with CAR-T Cells
Zhang, H., Ye, Z., Yuan, Z.-G., Luo, Z.-Q., Jin, H., & Qian, Q. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14405 · Cited by 109
“Studies have showed that genetically modified T cells with the expression of FAP-specific CAR can effectively recognize and kill FAP-positive tumor cells [115].”
BackgroundCrosstalk between cancer‐associated fibroblasts and immune cells in cancer
An, Y., Liu, F., Chen, Y., & Yang, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14745 · Cited by 98
Hsia, L.-T., Ashley, N., Ouaret, D., Wang, L. M., Wilding, J., & Bodmer, W. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603534113 · Cited by 99
Hussain, A., Voisin, V., Poon, S., Karamboulas, C., Bui, N. H. B., Meens, J., Dmytryshyn, J., Ho, V. W., Tang, K. H., Paterson, J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191094 · Cited by 108
“More recently, CAFs have also been shown to mediate immune suppression (Fearon, 2014; Kraman et al., 2010; Yang et al., 2016), adding another layer of complexity to their protumorigenic role.”
BackgroundResultLohela, M., Casbon, A.-J., Olow, A., Bonham, L., Branstetter, D., Weng, N., Smith, J., & Werb, Z. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419899111 · Cited by 95
“It is likely that nonimmune cell types, such as carcinoma-associated fibroblasts, may be the key trophic stromal cells (1, 59).”
BackgroundEnhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment
Kershaw, M. H., Devaud, C., John, L. B., Westwood, J. A., & Darcy, P. K. (2013) · OncoImmunology · doi:10.4161/onci.25962 · Cited by 102
Immunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 106
“Evidence supports the notion that stromal cells play an essential role in suppressing antitumor immune response [133,134]; thereby the immunotherapeutic potential of these cells have caught the attention of immunotherapists.”
BackgroundCao, Z., Quazi, S., Arora, S., Osellame, L. D., Burvenich, I. J. G., Janes, P. W., & Scott, A. M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01099-2 · Cited by 100
Blache, C. A., Manuel, E. R., Kaltcheva, T. I., Wong, A. N., Ellenhorn, J. D. I., Blazar, B. R., & Diamond, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0193 · Cited by 98
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.